1288th OGM and Open Lecture
The role of Helicobacter Pylori in Peptic Ulcer Disease
Professors Thomas Borody and Adrian Lee
Centre for Digestive Diseases (1) and UNSW Sydney (2)
This is the first presentation in the series How Good is NSW, a sequence of presentations documenting past and present discoveries that have made a difference. In it, Professors Lee and Borody will tell little known stories of the essential contributions by RSNSW Fellows to one of the greatest medical advance in our times.
In 1982 Robin Warren and Barry Marshall at the Royal Perth Hospital described the presence of squiggly bacteria in the gastric mucosa of patients with Peptic Ulcer Disease (PUD).Helicobacter pylori was on the map! They would deservedly be awarded the Nobel Prize for their discovery, which would change the world – medicine would never be the same again. It is not possible for even the modern generation of gastroenterologists to appreciate the way PUD dominated the lives of both patients and doctors 50 years ago — surgical lists were full of patients for gastrectomy, medical wards with patients with uncontrolled pain and complications. Twenty percent of men had a Duodenal Ulcer. Emergency rosters meant bleeding or perforated ulcers. Yet today, PUD is rarely seen – a recent analysis of the impact of H. pylori and its eradication over 25 years in Australia shows a saving of 19,000 deaths, and $10B in costs.
Warren and Marshall would have struggled to develop their ideas without the professional support of Professor Adrian Lee, with a long history of study of “squiggly” bacteria in the gut. His experience in the growth of these bacteria, their role in animal models, and his contributions to diagnosis, vaccine development and the link to cancer, added to the biology and broad understanding of these bacteria, enabling interpretation of the Perth discovery in a biological context. Warren and Marshall understood the importance of eradication to prove causation, but were unable to develop sterilising therapy, so only an association could be claimed. Professor Tom Borody carefully trialled a series of antibiotics to develop the first effective antibiotic combination, enabling for the first time, proof of causation of duodenal ulcers. This began a long sequence of contributions to our understanding and treatment of PUD by Borody including addition of PPI’s, and development of “escape” therapy. He worked with the Newcastle group to develop the first “near-patient” “yes/no” test, and identified a role for the host response in conditioning outcomes of the “host-parasite” relationship.
For webinar details and more information…read more.